Contineum Therapeutics Inc (CTNM)

$4.01 -0.58 (-12.64%)
Market Cap 118.75M
Revenue (ttm) 0.00
Net Income (ttm) -42.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 224,800
Avg Vol 119,688
Day's Range N/A - N/A
Shares Out 25.87M
Stochastic %K 34%
Beta 0.52
Analysts Strong Sell
Price Target $23.80

Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-30...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 333 5280
Address:
3565 General Atomics Court, Suite 200, San Diego, United States
Pumpb0t
Pumpb0t Jun. 27 at 1:36 AM
$CTNM that's a fat flag
0 · Reply
Pumpb0t
Pumpb0t Jun. 26 at 9:06 PM
$EYEN $WAI $VIVK $CTNM 50%+ upside
0 · Reply
Orlandotrader
Orlandotrader Jun. 25 at 1:24 PM
$CTNM Delays are never good Short time. Out of position. Will revisit later in Third quarter when phase 1 will read out.
0 · Reply
Pumpb0t
Pumpb0t Jun. 24 at 2:32 PM
$CTNM let's go $6
0 · Reply
Pumpb0t
Pumpb0t Jun. 23 at 8:27 PM
$EYEN $CTXR $VIVK $MTEK $CTNM launch em
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 23 at 2:54 AM
$CTNM timeline Q2 2025: Topline data for PIPE‑791 PET receptor-occupancy study. • Q3 2025: Final patient completion in the PIPE‑307 VISTA RRMS trial. • Early 2026: Topline results from the PIPE‑791 chronic pain Phase 1b study. • H2 2025: Potential IND filing for CTX‑343.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 23 at 2:51 AM
$CTNM William Blair initiated coverage on June 20 with an Outperform (Buy) rating, emphasizing PIPE‑791 and PIPE‑307 trial catalysts expected in Q2/H2 2025 .
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 23 at 2:50 AM
$CTNM Upcoming Phase 1b PIPE‑791 PET trial results expected Q2 2025. Phase 2 PIPE‑307 VISTA trial topline data expected H2 2025
0 · Reply
Pumpb0t
Pumpb0t Jun. 22 at 8:28 PM
$VIVK $CTNM $CTXR $MTEK final picks for Monday continuation...
1 · Reply
Pumpb0t
Pumpb0t Jun. 21 at 3:01 PM
$CTNM $FLYE $CTXR $MTEX sitting pretty
0 · Reply
Latest News on CTNM
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Jun 25, 2025, 8:15 AM EDT - 1 day ago

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 15, 2025, 4:05 PM EDT - 6 weeks ago

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

May 14, 2025, 4:05 PM EDT - 6 weeks ago

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Apr 28, 2025, 4:05 PM EDT - 2 months ago

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Mar 17, 2025, 4:05 PM EDT - 3 months ago

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Mar 12, 2025, 4:05 PM EDT - 3 months ago

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Mar 6, 2025, 4:05 PM EST - 4 months ago

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Mar 4, 2025, 4:05 PM EST - 4 months ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 4 months ago

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Jan 8, 2025, 4:05 PM EST - 6 months ago

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Dec 16, 2024, 4:05 PM EST - 6 months ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Nov 25, 2024, 8:05 AM EST - 7 months ago

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Nov 18, 2024, 8:05 AM EST - 7 months ago

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Contineum Therapeutics to Attend Upcoming Investor Conferences

Nov 13, 2024, 4:05 PM EST - 8 months ago

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 4:05 PM EST - 8 months ago

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Aug 28, 2024, 4:05 PM EDT - 10 months ago

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 13, 2024, 4:05 PM EDT - 11 months ago

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Jul 31, 2024, 4:05 PM EDT - 11 months ago

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Jun 24, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

RNA

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Jun 13, 2024, 2:03 PM EDT - 1 year ago

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

May 20, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 16, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

Apr 6, 2024, 5:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

JNJ LOAR MAMO PACS RBRK ULS ZBAO

Contineum Therapeutics Announces Pricing of Initial Public Offering

Apr 4, 2024, 9:02 PM EDT - 1 year ago

Contineum Therapeutics Announces Pricing of Initial Public Offering

Pumpb0t
Pumpb0t Jun. 27 at 1:36 AM
$CTNM that's a fat flag
0 · Reply
Pumpb0t
Pumpb0t Jun. 26 at 9:06 PM
$EYEN $WAI $VIVK $CTNM 50%+ upside
0 · Reply
Orlandotrader
Orlandotrader Jun. 25 at 1:24 PM
$CTNM Delays are never good Short time. Out of position. Will revisit later in Third quarter when phase 1 will read out.
0 · Reply
Pumpb0t
Pumpb0t Jun. 24 at 2:32 PM
$CTNM let's go $6
0 · Reply
Pumpb0t
Pumpb0t Jun. 23 at 8:27 PM
$EYEN $CTXR $VIVK $MTEK $CTNM launch em
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 23 at 2:54 AM
$CTNM timeline Q2 2025: Topline data for PIPE‑791 PET receptor-occupancy study. • Q3 2025: Final patient completion in the PIPE‑307 VISTA RRMS trial. • Early 2026: Topline results from the PIPE‑791 chronic pain Phase 1b study. • H2 2025: Potential IND filing for CTX‑343.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 23 at 2:51 AM
$CTNM William Blair initiated coverage on June 20 with an Outperform (Buy) rating, emphasizing PIPE‑791 and PIPE‑307 trial catalysts expected in Q2/H2 2025 .
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 23 at 2:50 AM
$CTNM Upcoming Phase 1b PIPE‑791 PET trial results expected Q2 2025. Phase 2 PIPE‑307 VISTA trial topline data expected H2 2025
0 · Reply
Pumpb0t
Pumpb0t Jun. 22 at 8:28 PM
$VIVK $CTNM $CTXR $MTEK final picks for Monday continuation...
1 · Reply
Pumpb0t
Pumpb0t Jun. 21 at 3:01 PM
$CTNM $FLYE $CTXR $MTEX sitting pretty
0 · Reply
Bentradez
Bentradez Jun. 20 at 9:34 PM
$CTNM push over 5, continuation Monday
0 · Reply
Quantumup
Quantumup Jun. 18 at 8:44 PM
William Blair🏁 $CTNM Outperform-$23.26 and said, "We are initiating coverage of Contineum Therapeutics with an Outperform rating and fair value of $23.26 per share." $BMY $JNJ $TGTX RHHBY $AXSM LLY PFE ABBV GSK TAK William Blair went on to say:
0 · Reply
Alfred_Penny_worth
Alfred_Penny_worth Jun. 11 at 7:29 PM
$BHAC $TMC... $HUBC... $TOYO... $CTNM... SPACs always do this after merger. Biggest scams on the market.
1 · Reply
Orlandotrader
Orlandotrader Jun. 7 at 1:07 AM
$CTNM Just the Start
0 · Reply
deucestwits
deucestwits Jun. 6 at 2:40 AM
$CTNM
0 · Reply
moontomorrow
moontomorrow Jun. 2 at 5:59 PM
$CTNM what's the reason for the 20% pop today? anyone have any news?
0 · Reply
deucestwits
deucestwits Jun. 2 at 2:03 PM
$CTNM very quiet….
0 · Reply
Foster_Craig
Foster_Craig May. 21 at 6:54 PM
$CTNM
0 · Reply
moontomorrow
moontomorrow May. 20 at 3:04 AM
$CTNM they are presenting tomorrow at 8.30am ET at 2025 RBC Healthcare Conference.
0 · Reply
floathead
floathead May. 19 at 6:20 PM
$CTNM
0 · Reply
Orlandotrader
Orlandotrader May. 19 at 5:37 PM
$CTNM Nice
0 · Reply
tommyrulz
tommyrulz May. 15 at 8:39 PM
$CTNM 2 huge 13G holdings just were filed with SEC. Institutions backing up the truck. 💪
2 · Reply